COMMUNIQUÉS West-GlobeNewswire

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
01/03/2024
- Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 - - Dosing of first patient in the expanded Phase 2a portion of Phase 1/2a trial of IMM-1-104 expected in March 2024; [...]
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
01/03/2024
NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI [...]
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
01/03/2024
NEW HAVEN, Conn., March 01, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and [...]
iTeos to Participate in Upcoming Investor Conferences
01/03/2024
WATERTOWN, Mass. and GOSSELIES, Belgium, March 01, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new [...]
iTeos annonce sa participation aux prochaines journées Investisseurs
01/03/2024
WATERTOWN, Massachusetts et GOSSELIES, Belgique, 01 mars 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), une société biopharmaceutique au stade clinique pionnière dans la découverte et le [...]
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
01/03/2024
Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic malignancies Follows ongoing clinical study of CLN-619 alone and in [...]
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
01/03/2024
PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March. Cowen [...]
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
01/03/2024
HOUSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of [...]
Immunocore to present at upcoming investor conferences
01/03/2024
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 March 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a [...]
Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance
01/03/2024
Reports fourth quarter 2023 total revenue of $6.3 million , representing 45% growth compared to fourth quarter 2022 Reports 2023 revenue of $22.5 million , representing 31% growth compared to 2022 Delivered 2023 [...]
Powerful Medical Secures €7.5M in Funding from European Innovation Council to Revolutionize Heart Attack Diagnostics with AI
01/03/2024
Powerful Medical, a pioneering medical device manufacturer, proudly announces being selected to receive a €2.5 million grant and a follow-on €5 million investment from the European Innovation Council (EIC) . Chosen from [...]
Tarsus Announces Pricing of $100.0 Million Public Offering
01/03/2024
IRVINE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to [...]
Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock
01/03/2024
DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today [...]
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
01/03/2024
HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its [...]
RxSight, Inc. to Participate in the 34th Annual Oppenheimer Healthcare Conference
01/03/2024
ALISO VIEJO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
CORRECTION - Theratechnologies annonce la démission de l’un de ses administrateurs, M. Alain Trudeau
29/02/2024
MONTRÉAL, 29 févr. 2024 (GLOBE NEWSWIRE) -- Aujourd’hui, Theratechnologies Inc. (TSX : TH) (NASDAQ : THTX) a diffusé un communiqué de presse que le présent document sous le même titre corrige et remplace. Veuillez noter [...]
Scilex Holding Company Announces $10 Million Bought Deal Offering
29/02/2024
PALO ALTO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]
Spectral AI Appoints Peter M. Carlson as CEO
29/02/2024
Appointment Paves the Way for Company’s Next Chapter in Commercialization Phase of AI-Powered DeepView Device for Predictive Wound Care Carlson Brings Proven Track Record of Operating and Financial Leadership, Including [...]
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
29/02/2024
WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]

Pages